Introduction
In patients with systemic diseases bone mineral density is diminished due to the underlaying disease, the secondary loss of bone mass, the diminution of mobility and the treatment with steroids. Biphosphonates inhibit bone resorption: they produce reduction of the apoptosis in osteoblasts and induce apoptosis in osteoclasts [1, 2] .
Objective
To value the effectiveness of the treatment with intravenous pamidronate in children with secondary osteoporosis or osteopenia to rheumatic diseases.
Materials and methods
Retrospective analytical study: 22 children, ages between the 4 and 17 years and clinical diagnosis of osteopenia, osteoporosis, calcinosis secondary to rheumatic diseases (Juvenile Idiopatic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomiositis, Overlap Syndrome, Panarteritis Nodosa, Familiar Mediterranean Fever). Criteria of inclusion: the patients had to fulfill the criteria of osteopenia and osteoporosis defined according to z-score or bone mineral density; and the diagnostic criteria of the referred diseases. Information about the underlaying disease, the treatment received and steroids' dose and duration was collected. The administration of intravenous pamidronate was made according to the protocol established by Glorieux et al.
Results
All the patients treated with intravenous pamidronate presented a significant increase in bone mineral density, clinical improvement, decrease of the number of fractures, reduction in bone pain and improvement of the quality of life. In all the patients with calcinosis a reduction was observed and in one patient it even disappeared.
